# Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer

> **NCT00264134** · PHASE1,PHASE2 · TERMINATED · sponsor: **Kentuckiana Cancer Institute** · enrollment: 40 (—)

## Conditions studied

- Non-small Cell Lung Cancer
- Extensive Stage Unresectable

## Interventions

- **DRUG:** Docetaxel
- **DRUG:** Irinotecan
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT00264134
- **Lead sponsor:** Kentuckiana Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2003-06
- **Primary completion:** —
- **Final completion:** 2005-10
- **Target enrollment:** 40 (—)
- **Last updated:** 2010-01-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00264134

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00264134, "Docetaxel, Irinotecan, and Carboplatin in Extensive Stage Non-Small Cell Lung Cancer". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00264134. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*